Adaptive Sampling Advances Pediatric Cancer Profiling - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Adaptive Sampling Advances Pediatric Cancer Profiling

  • November 16, 2026

  • 3 min

Share

Clinical Scorecard: Adaptive Sampling Advances Pediatric Cancer Profiling

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: Adaptive Sampling Advances Pediatric Cancer Profiling
Key MechanismsMechanisms or clinical associations described in the source article.
Target PopulationPatients or participants described in the source article.
Care SettingDiagnostic laboratory evaluation of pediatric cancers; further clinical validation is needed to establish whether AS-WGS can replace existing diagnostic workflows.

Key Highlights

  • The researchers estimated sequencing costs at approximately CAD $1,700 per sample, compared with more than CAD $5,000 for combined conventional approaches.

Guideline-Based Recommendations

Diagnosis

  • The study evaluated AS-WGS as a single assay for detecting gene fusions, mutations, large copy-number alterations, and DNA methylation patterns in pediatric cancer samples.
  • The researchers developed the open-source nf-core-oncoseq pipeline to support interpretation while sequencing was underway.

Management

  • The lead researcher said earlier molecular profiling could support timely risk stratification and tailored treatment decisions; further clinical validation is needed to establish whether the approach can replace existing workflows and improve treatment decisions.

Monitoring & Follow-up

  • The lead researcher said real-time sequencing and analysis can provide initial clinically relevant insights within hours, with comprehensive molecular profiles available within days.
  • The source reports that detecting low-frequency mutations could require up to 72 hours of sequencing.

Risks

  • Some variants required manual review.
  • DNA quality and sequencing performance affected results.
  • Further clinical validation is needed to establish whether AS-WGS can replace existing diagnostic workflows and improve treatment decisions.

Patient & Prescribing Data

The study included 35 pediatric patients and 36 samples; 31 samples were tumors representing leukemias and solid cancers.

No treatment regimen or prescribing outcomes were reported. The lead researcher stated that earlier molecular profiling could support timely risk stratification and tailored treatment decisions.

Clinical Best Practices

  • Interpret the reported performance in the context of the study's 36 samples and the need for further clinical validation.
  • The source reports that DNA quality and sequencing performance affected results.
  • Some variants required manual review.
  • The source reports that detecting low-frequency mutations could require up to 72 hours of sequencing.

Related Resources & Content

Original Source(s)

Related Content